Compare Amylx Pharmaceuticals Inc (AMLX) vs National Beverage Corp. (FIZZ) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amylx Pharmaceuticals Inc vs National Beverage Corp. — how do they compare? Amylx Pharmaceuticals Inc trades at $17.77 (market cap $1.98B), while National Beverage Corp. trades at $30.71 (market cap $3.17B). The key difference: National Beverage Corp. is the larger of the two by market cap, and Amylx Pharmaceuticals Inc is trading nearer its 52-week high, National Beverage Corp. nearer its low. Which is the better fit depends on your goals.
| AMLX | FIZZ | |
|---|---|---|
Market Cap | $1.98B | $3.17B |
Sector | Health | Consumer Cyclical |
52-Week High | $18.70 | $47.69 |
52-Week Low | $7.64 | $31.00 |
Enterprise Value | $1.70B | $2.87B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMLX trades at $17.77, down 3.32% today, with a bullish technical signal from moving averages and strong analyst support. The company is in a pivotal phase with key Phase 3 data for avexitide expected in Q3 2026, targeting a potential 2027 launch. Financially, it shows significant losses with negative ROE and ROA, but cash flow from financing activities provides runway. Recent news highlights clinical progress and conference presentations, alongside ongoing class action settlement discussions.
The outlook hinges on successful clinical trial outcomes, particularly avexitide's Phase 3 readout, which could drive substantial upside toward the $30.50 consensus price target. However, high execution risk, persistent cash burn, and legal overhangs pose threats to near-term stability. Investor sentiment remains cautiously optimistic given the 90.9% buy rating from analysts, but the stock is speculative until profitability milestones are achieved.
National Beverage Corp (FIZZ) trades at $33.82, up 3.93% today, showing mixed signals with bearish technical indicators but strong profitability metrics including 15.56% net margin and 34.03% ROE. Recent Q2 2026 earnings missed expectations, but the company declared a $3.25 special dividend payable July 30, 2026. Cash flow trends show volatility, with 2025 net cash flow negative $133 million due to significant financing outflows.
The outlook remains cautious with analyst consensus leaning bearish (50% sell ratings) despite solid fundamentals. Key risks include competitive pressures and consumer weakness, while the special dividend provides near-term shareholder value. Investors should weigh strong profitability against recent earnings misses and negative cash flow trends.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amylx Pharmaceuticals Inc
Amylyx Pharmaceuticals is a biopharmaceutical firm focused on developing therapies for rare diseases. Its pipeline includes treatments for conditions like post-bariatric hypoglycemia and congenital hyperinsulinism.
Read more on AMLX →About National Beverage Corp.
National Beverage Corp is one of the top 10 non-alcoholic beverage companies in the U.S. Its portfolio skews toward functional drinks (that is those purporting to offer health benefits) and is anchored by the popular LaCroix sparkling water trademark. Other offerings include Rip It energy drinks, Everfresh juices, and soda brands like Shasta and Faygo. The firm controls most of its production and distribution apparatus, with very little outsourcing. In terms of go-to-market, it uses warehouse distribution for big-box retailers, direct-store-delivery for convenience stores and other small outlets, and food-service distributors for the food-service channel (schools, hospitals, restaurants). It is controlled by chairman and CEO Nick Caporella, who owns over 73% of the common stock.
Read more on FIZZ →
